Our results suggested that uncommon EGFR-mutant NSCLC can be further stratified into various mutation subgroups which exhibit distinct therapeutic responses and survival outcomes to EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.